AOD-9604 in Cateel — Fat Loss Peptide Research Guide
AOD-9604 research guide for Cateel. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
The hunt for AOD-9604 in Cateel reliably produces the same conclusion: research peptides are sourced from specialist online vendors, not local pharmacies. The upside of this online-only market is that serious vendors differentiate entirely through their analytical documentation, giving researchers better verification tools than local retail ever could. The primary quality indicators for AOD-9604 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. This guide takes Cateel researchers through that evaluation process and explains the signals that distinguish quality AOD-9604 suppliers.
AOD-9604: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Cateel comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade AOD-9604
Before evaluating any specific vendor, understand what genuine quality documentation contains — so you can recognise whether a vendor meets it. When reviewing a AOD-9604 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are below the threshold for research use. For Cateel researchers evaluating new suppliers: a modest first purchase to test the product before placing larger orders is the accepted approach among experienced researchers. For Cateel researchers making a first AOD-9604 purchase: verify the vendor against this framework, begin with a small order, and verify batch traceability on arrival before use.
Order AOD-9604 — ships to Cateel
COA-verified · International tracking · Research grade
All use of AOD-9604 in Cateel or anywhere is research use only — this compound is not approved for human therapeutic use, and all handling should comply with standard research safety practices. Storage requirements for AOD-9604: lyophilised powder at −20°C, reconstituted solution stored refrigerated at 2-8°C and finished within 30 days of reconstitution; reconstitute only with bac water. Verify the endotoxin level in your AOD-9604 batch COA before any protocol involving administration — look for results reported in endotoxin units per mg or mL and verify they are within the acceptable range for your research context. PubMed and related preprint servers are the primary literature resources for AOD-9604 research; focus on peer-reviewed publications with documented compound quality over unreviewed preprints or forum reports.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
